Arimoclomol

Arimoclomol (brand name Miplyffa) is an FDA-approved oral medication, approved in September 2024, to treat neurological symptoms of Niemann-Pick disease type C (NPC) in adults and children 2 years and older, used in combination with miglustat. It acts as a heat-shock protein-70 (HSP70) co-inducer to repair cells.